French bill tightens up on safety and conflicts of interest, but not drug approval criteria
This article was originally published in SRA
Executive Summary
Longer waits before starting promotional campaigns, higher costs associated with new product approvals, and a sharp fall in sales rep employment levels: All are in prospect for the pharmaceutical industry if the new French bill on regulatory reform is passed in its present form1.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.